Short Interest in COMPASS Pathways plc (NASDAQ:CMPS) Expands By 17.5%

COMPASS Pathways plc (NASDAQ:CMPS) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 4,240,000 shares, a growth of 17.5% from the May 31st total of 3,610,000 shares. Based on an average daily volume of 497,900 shares, the short-interest ratio is presently 8.5 days.

Insider Buying and Selling

In related news, major shareholder George Jay Goldsmith sold 9,621 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $8.29, for a total transaction of $79,758.09. Following the completion of the transaction, the insider now owns 3,966,052 shares of the company’s stock, valued at approximately $32,878,571.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.25% of the stock is owned by insiders.

Institutional Investors Weigh In On COMPASS Pathways

A number of large investors have recently bought and sold shares of CMPS. Quest Partners LLC bought a new stake in COMPASS Pathways during the 4th quarter worth approximately $33,000. Conservest Capital Advisors Inc. bought a new stake in COMPASS Pathways during the 4th quarter worth approximately $91,000. TAP Consulting LLC grew its position in COMPASS Pathways by 14.7% during the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after acquiring an additional 1,645 shares during the last quarter. EWA LLC bought a new stake in COMPASS Pathways during the 4th quarter worth approximately $107,000. Finally, Kennedy Capital Management LLC bought a new stake in COMPASS Pathways during the 1st quarter worth approximately $139,000. 46.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CMPS shares. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Morgan Stanley started coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an “overweight” rating and a $30.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research note on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Price Performance

Shares of CMPS stock traded down $0.09 during trading hours on Monday, hitting $5.95. The company had a trading volume of 315,738 shares, compared to its average volume of 583,558. COMPASS Pathways has a 12 month low of $5.01 and a 12 month high of $12.75. The firm has a market capitalization of $406.86 million, a price-to-earnings ratio of -2.51 and a beta of 2.28. The firm’s fifty day moving average is $7.41 and its 200 day moving average is $8.87. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.03). On average, sell-side analysts predict that COMPASS Pathways will post -2.24 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.